Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

4CPS-176 Use and persistence of guselkumab in treatment for rheumatic and dermatological disease

View Full Paper
Ask AI
Bookmark
Share

Authors

PFP Ortíz FernándezAFAnabel Herreros FernándezPFP Fernandez-Villacañas Fernandez

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fernández et al. (2024) studied this question.

synapsesocial.com/papers/68e7660bb6db6435876db9dehttps://doi.org/10.1136/ejhpharm-2024-eahp.280
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-116 Real-world persistence with guselkumab among adults with psoriatic arthritis2024
  2. 24CPS-085 Long-term persistence in psoriasis patients with high response to guselkumab: a real-world retrospective study2024
  3. 3Guselkumab effectiveness in real world settings: observations from an Italian multi-center study2025 · 2 citations
  4. 4Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors2024 · 7 citations
  5. 5The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study2024 · 10 citations